Alzamend Neuro(ALZN)
$1.30-0.01 (-0.76%)
ALZN
Alzamend Neuro financials statements
$1.30
At close:-0.01 (-0.76%)
Alzamend Neuro (ALZN) Ratios
433 Followers
Alzamend Neuro Ratios
ALZN's free cash flow for Q1 2027 was $-1.14M. For the 2027 fiscal year, ALZN's free cash flow was increased by $0.00 and operating cash flow was $-1.14M. See a summary of the company’s cash flow.
| Ratios | Apr 26 | Apr 25 | Apr 24 | Apr 23 | Apr 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.31 | 6.58 | 0.14 | 2.03 | 12.37 |
| Quick Ratio | 1.31 | 6.58 | 0.14 | 2.03 | 12.37 |
| Cash Ratio | 0.53 | 6.22 | 0.12 | 1.79 | 12.07 |
| Solvency Ratio | -6.43 | -7.03 | -3.07 | -5.18 | -10.61 |
| Operating Cash Flow Ratio | -5.99 | -10.35 | -2.56 | -3.11 | -5.68 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -27.50 | 0.00 | 0.00 |
| Net Current Asset Value | $ 418.35K | $ 3.54M | $ -2.77M | $ 2.97M | $ 13.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.48 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.12 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -0.13 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.84 | 1.16 | -0.24 | 1.94 | 1.09 |
| Debt Service Coverage Ratio | 1307.60 | -246.61 | -31.81 | -1927.93 | -264.72 |
| Interest Coverage Ratio | 1324.50 | -249.42 | -983.86 | -1930.92 | -264.81 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | -0.00 | 0.05 | 0.09 | 0.00 | 0.02 |
| Net Debt to EBITDA | 0.08 | 0.89 | 0.01 | 0.35 | 1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.06% | 100.40% | 100.10% | 100.05% | 100.34% |
| Return on Assets (ROA) | -421.88% | -98.09% | -1575.08% | -251.50% | -85.16% |
| Return on Equity (ROE) | -1196.43% | -113.78% | 383.47% | -488.52% | -92.59% |
| Return on Capital Employed (ROCE) | -1195.68% | -113.32% | 383.09% | -488.26% | -92.27% |
| Return on Invested Capital (ROIC) | -1195.68% | -113.32% | 433.32% | -488.26% | -92.27% |
| Return on Tangible Assets | -421.88% | -98.09% | -1575.08% | -251.50% | -85.16% |
| Earnings Yield | -230.59% | -190.97% | -4.60% | -0.64% | -0.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.42 | -16.50 | -2.45 | -2.75 | -2.23 |
| Free Cash Flow Per Share | -2.42 | -17.26 | -2.49 | -2.75 | -2.27 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -21.89 | -56.17 | 0.00 | -62.13 |
| Capital Expenditure Coverage Ratio | 0.00 | -21.89 | -56.17 | 0.00 | -62.13 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -27.50 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -212.07% | -290.52% | -3.89% | -0.38% | -0.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.43 | -0.52 | -21.74 | -156.67 | -330.27 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.19 | 0.60 | -83.37 | 765.37 | 305.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.47 | -0.34 | -25.70 | -261.22 | -607.52 |
| Price-to-Operating Cash Flow Ratio | -0.47 | -0.36 | -26.15 | -261.22 | -617.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | -0.04 | 1.76 | -0.15 |
| Enterprise Value Multiple | -0.36 | 0.36 | -21.87 | -156.65 | -330.36 |
| Enterprise Value | 3.09M | -1.58M | 216.21M | 2.33B | 4.07B |
| EV to EBITDA | -0.36 | 0.36 | -21.87 | -156.65 | -330.36 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.38 | 0.23 | -25.69 | -260.65 | -605.43 |
| EV to Operating Cash Flow | -0.38 | 0.24 | -26.14 | -260.65 | -615.17 |
| Tangible Book Value Per Share | 0.22 | 9.97 | -0.77 | 0.94 | 4.50 |
| Shareholders’ Equity Per Share | 0.22 | 9.97 | -0.77 | 0.94 | 4.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.63 | -11.34 | -2.94 | -4.58 | -4.17 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 1.45 | 0.83 | 0.60 | 0.54 |
Currency in USD
